Evidence-aware
Safety focused
Women’s Health Clinic FAQ
Can the O-Shot help with menopause symptoms?
The O-Shot may be discussed for selected intimate symptoms that can overlap with menopause, such as dryness, comfort, sensitivity, or bladder leakage, but it is not a menopause treatment as a whole.
Direct answer
The O-Shot may be discussed for selected intimate symptoms that can overlap with menopause, such as dryness, comfort, sensitivity, or bladder leakage, but it is not a menopause treatment as a whole.
The most useful plan starts with the underlying cause, not the treatment name. Your clinician should review symptoms, medical history, alternatives, expected benefits, limitations and safety.
Educational only. Suitability must be confirmed after consultation. Results vary. Not a cure.
At a glance
These are the main points to understand before deciding whether this option is suitable.
At a glance
Clinical summary
Treatment Type
Non-surgical, minimally invasive autologous blood injection.
Target Areas
The clitoris and anterior vaginal wall/G-spot area.
Key Mechanism
Utilizes growth factors in blood platelets to trigger cellular repair and tissue rejuvenation.
Primary Menopause Indications
Vulvovaginal atrophy (VVA), vaginal dryness, painful sex, and mild urinary leakage.
Important safety note
Common Side Effects: Mild and temporary swelling, redness, tenderness, or minor bruising at the injection sites, which usually resolve in a few days.
Suitability
Evidence
Safety
Aftercare
Detailed answer
Detailed answer
• Investigational Status: The O-Shot is considered an 'off-label' and investigational application of autologous blood products, meaning it lacks the large-scale, long-term randomised controlled trials (RCTs) required for inclusion in standard NHS/NICE guidelines.
Clinical context
Investigational Status: The O-Shot is considered an 'off-label' and investigational application of autologous blood products, meaning it lacks the large-scale, long-term randomised controlled trials (RCTs) required for inclusion.
Evidence
Symptoms
Alternatives
What it means
Investigational Status: The O-Shot is considered an 'off-label' and investigational application of autologous blood products, meaning it lacks the large-scale, long-term randomised controlled trials (RCTs) required for inclusion.
Why it happens
Efficacy: While pilot studies and smaller RCTs show reported subjective improvements for GSM and incontinence, it cannot be viewed as a definitive treatment.
Evidence limits
Holistic Approach: It improves physiological factors like tissue health and blood flow, but sexual response remains multifactorial, involving psychological and hormonal elements.
Treatment fit
Synergy with Standard Care: PRP therapy can be combined, where clinically appropriate, with topical vaginal oestrogen, pelvic floor physiotherapy, or systemic HRT for a comprehensive approach to menopause.
What this means in practice
• Availability: The procedure is not available on the NHS for sexual dysfunction or incontinence; it is exclusively offered in private clinics. • Costs should be confirmed on the /pricing/ page before booking
• Procedure Duration: Typically takes 30 to 60 minutes from start to finish, including the blood draw and numbing phases. • Initial Results: Some patients report improvements in sensitivity and lubrication within a few days to 4–6 weeks.
Patient safety
Why proper assessment matters
Assessment helps separate marketing claims from safe, individualised clinical decision-making.
It checks the cause
Investigational Status: The O-Shot is considered an 'off-label' and investigational application of autologous blood products, meaning it lacks the large-scale, long-term randomised controlled trials (RCTs) required for inclusion.
It protects safety
Common Side Effects: Mild and temporary swelling, redness, tenderness, or minor bruising at the injection sites, which usually resolve in a few days.
It reviews alternatives
Availability: The procedure is not available on the NHS for sexual dysfunction or incontinence; it is exclusively offered in private clinics.
It sets expectations
Procedure Duration: Typically takes 30 to 60 minutes from start to finish, including the blood draw and numbing phases.
A clinical decision, not a shortcut
The safest final page should explain what the intervention may do, what it cannot promise, and when another route may be better.
Treatment should be discussed with realistic goals, informed consent, clear aftercare and a plan for review.
Considerations
What to consider
• Availability: The procedure is not available on the NHS for sexual dysfunction or incontinence; it is exclusively offered in private clinics. • Costs should be confirmed on the /pricing/ page before booking
Consultation priorities
Consultation: A thorough clinical assessment to discuss medical history, specific menopausal symptoms, expectations, and alternatives.
Consent
Aftercare
Follow-up
Before treatment
Consultation: A thorough clinical assessment to discuss medical history, specific menopausal symptoms, expectations, and alternatives.
During care
Preparation: A standard blood draw from the arm, alongside the application of medical-grade topical numbing cream or a local lidocaine block to the treatment area for about 20.
Aftercare
Centrifugation: The blood sample is processed in a centrifuge for 5–10 minutes to extract the platelet-rich plasma.
When to reassess
Injection: The concentrated PRP is precisely injected into the clitoris and anterior vaginal wall/G-spot using fine-gauge needles, taking less than 5 minutes.
Practical expectations
Procedure Duration: Typically takes 30 to 60 minutes from start to finish, including the blood draw and numbing phases.
Costs should be confirmed on the /pricing/ page before booking
Common concerns and myths
Common misconceptions
Clear patient information should correct over-simple claims and keep expectations realistic.
Myth: The O-Shot treats menopause itself.
Reality: suitability depends on the symptom pattern, medical history, contraindications, alternatives and individual goals.
Myth: All menopause-related sexual symptoms have the same cause.
Reality: results vary, evidence may be developing, and non-response should prompt reassessment.
Myth: PRP removes the need to discuss hormone or bladder care.
Reality: injections, devices and intimate procedures can still carry risks and need proper consent and aftercare.
Evidence and advertising
Efficacy: While pilot studies and smaller RCTs show reported subjective improvements for GSM and incontinence, it cannot be viewed as a definitive treatment.
Alternatives
Availability: The procedure is not available on the NHS for sexual dysfunction or incontinence; it is exclusively offered in private clinics.
Safety checklist
Safety checklist
Use these questions to decide whether treatment should be discussed, delayed or redirected.
Has the cause been assessed?
Symptoms should be reviewed in context before selecting a treatment.
Are red flags absent?
Common Side Effects: Mild and temporary swelling, redness, tenderness, or minor bruising at the injection sites, which usually resolve in a few days.
Are alternatives clear?
Availability: The procedure is not available on the NHS for sexual dysfunction or incontinence; it is exclusively offered in private clinics.
Is follow-up planned?
The clinic should explain aftercare, review timing and when to seek help.
Reassuring signs
Proceeding is more reasonable when goals are clear, red flags have been checked, and expectations are realistic.
No red flags
Follow-up plan
Reasons to pause
Common Side Effects: Mild and temporary swelling, redness, tenderness, or minor bruising at the injection sites, which usually resolve in a few days.
Bleeding
Infection
When to escalate
When to seek medical help
Some symptoms should be assessed before any elective intimate treatment. Use NHS 111 online
Severe or worsening pain
Common Side Effects: Mild and temporary swelling, redness, tenderness, or minor bruising at the injection sites, which usually resolve in a few days.
Bleeding or discharge
Contraindications: Not suitable for individuals with active pelvic infections, severe pelvic organ prolapse (Grade 3 or 4), bleeding disorders, untreated cancer, or those who are pregnant.
Infection signs
Red Flags (Seek Immediate Care): Severe or worsening throbbing pain, heavy bleeding (e. g.
Emergency symptoms
Call 999 in a life-threatening emergency, including collapse, chest pain or breathing difficulty.
Use NHS 111 for urgent advice or call 999 in a life-threatening emergency. This page is educational and does not replace individual medical assessment.
More clinical detail
Benchmark positioning
- The strongest page wins by saying clearly what the O-Shot may be relevant to, and what belongs in broader menopause medical care.
Clinical reality
- Investigational Status: The O-Shot is considered an 'off-label' and investigational application of autologous blood products, meaning it lacks the large-scale, long-term randomised controlled trials (RCTs) required for inclusion in standard NHS/NICE guidelines.
- Efficacy: While pilot studies and smaller RCTs show reported subjective improvements for GSM and incontinence, it cannot be viewed as a definitive treatment.
- Holistic Approach: It improves physiological factors like tissue health and blood flow, but sexual response remains multifactorial, involving psychological and hormonal elements.
- Synergy with Standard Care: PRP therapy can be combined, where clinically appropriate, with topical vaginal oestrogen, pelvic floor physiotherapy, or systemic HRT for a comprehensive approach to menopause symptoms.
Timeline and expectations
- Procedure Duration: Typically takes 30 to 60 minutes from start to finish, including the blood draw and numbing phases.
- Initial Results: Some patients report improvements in sensitivity and lubrication within a few days to 4–6 weeks.
- Peak Results: reported tissue response and symptom change typically develop around 3 months post-treatment.
- Longevity: Benefits generally last up to 12 to 18 months, with many women opting for annual maintenance sessions to sustain results.
- Downtime: usually limited; most daily activities and sexual intercourse can be resumed immediately or within 48 hours to 3 days depending on specific clinic advice.
Practical logistics
- Availability: The procedure is not available on the NHS for sexual dysfunction or incontinence; it is exclusively offered in private clinics.
- Costs should be confirmed on the /pricing/ page before booking
- Equipment Quality: Providers must use CE/FDA-approved, medical-grade centrifuge kits (e.g., RegenLab or Magellan) to ensure a high, therapeutic platelet yield.
- Provider Certification: 'O-Shot' is a trademarked term; genuine O-Shots are performed by practitioners specifically trained and certified by the Cellular Medicine Association (CMA).
Research sources
- Chen AH, et al. (2025). Platelet-Rich Plasma for Genitourinary Syndrome of Menopause in Breast Cancer Survivors. Obstetrics & gynaecology, 146(5), 728-736.
- Atlihan U, et al. (2025). Comparison of topical oestrogen and platelet-rich plasma injections in the treatment of postmenopausal vaginal atrophy. Frontiers in Medicine, 12:1590078.
- Willison N, et al. (2025). Application of Platelet-Rich Plasma in Gynaecologic Disorders: A Scoping Review. Journal of Clinical Medicine, 14(16), 5832.
- Ahdoot M, et al. (2022). The O-Shot for Female Sexual Dysfunction: A Systematic Review. Aesthetic Surgery Journal Open Forum.
Regulatory resources
Authoritative resources
These resources support assessment-led, evidence-aware patient information.
NICE guidance on vaginal laser for urogenital atrophy
NICE is a UK authority for interventional procedure governance and supports cautious language about evidence, consent and audit.
FDA safety communication on vaginal rejuvenation devices
This safety communication is a useful regulatory reference for avoiding over-claiming around sexual enhancement procedures.
RCOG patient information on menopause symptom treatment
RCOG patient information supports assessment-led discussion of vaginal dryness, discomfort and hormone-related symptoms.
Next step
Book a clinical consultation
A consultation can confirm whether this treatment may be suitable, whether another pathway should come first, and what realistic outcomes and aftercare would look like.
▶ View Research Sources (12 Sources)
These 12 source names are selected from 24 display-ready sources, with a raw audit trail of 340 imported records. Additional reviewed material included professional society guidance, peer-reviewed clinical papers; duplicate, low-relevance and non-clinical records were removed before display.
Educational only. This information is intended for educational purposes only and does not substitute professional medical advice, diagnosis, or treatment. The O-Shot is an investigational, off-label procedure and individual results will vary. Always consult with a qualified healthcare provider to thoroughly evaluate your symptoms and explore all evidence-based therapies before pursuing regenerative injections. Results vary. Not a cure.
